Where is ZVSA stock listed?

ZyVersa Therapeutics, Inc. trades under the ticker ZVSA on OTC.

How can I research ZVSA's financials and filings?

Vantafin provides ZyVersa Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ZVSA profile.

ZyVersa Therapeutics, Inc. (ZVSA) stock profile

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Key facts

Symbol	ZVSA
Exchange	OTC
Sector	Healthcare
Industry	Biotechnology
CEO	Stephen C. Glover
Employees	7
Headquarters	Weston, FL, US
IPO	2022-02-11
Website	www.zyversa.com

Explore ZVSA on Vantafin

Frequently asked questions

What does ZyVersa Therapeutics, Inc. (ZVSA) do?: ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Where is ZVSA stock listed?: ZyVersa Therapeutics, Inc. trades under the ticker ZVSA on OTC.
How can I research ZVSA's financials and filings?: Vantafin provides ZyVersa Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ZVSA profile.

ZyVersa Therapeutics, Inc. (ZVSA) stock profile

Key facts

Symbol	ZVSA
Exchange	OTC
Sector	Healthcare
Industry	Biotechnology
CEO	Stephen C. Glover
Employees	7
Headquarters	Weston, FL, US
IPO	2022-02-11
Website	www.zyversa.com

Explore ZVSA on Vantafin

Frequently asked questions

What does ZyVersa Therapeutics, Inc. (ZVSA) do?: ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Where is ZVSA stock listed?: ZyVersa Therapeutics, Inc. trades under the ticker ZVSA on OTC.
How can I research ZVSA's financials and filings?: Vantafin provides ZyVersa Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ZVSA profile.